PureTech Health (PRTC) Non-Current Deffered Revenue (2019)
PureTech Health (PRTC) reported Non-Current Deffered Revenue of $1.2 million for Q4 2019.
PureTech Health (PRTC) has 1 years of Non-Current Deffered Revenue data on file, last reported at $1.2 million in Q4 2019.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.2 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $1.2 million (changed N/A YoY) and the FY2019 annual result came in at $1.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $1.2 million in Q4 2019 per PRTC's latest filing.
- Across five years, Non-Current Deffered Revenue topped out at $1.2 million in Q4 2019 and bottomed at $1.2 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 225.10 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.22 Mn |